A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.

NCT06470191

Status	RECRUITING
Phase	Phase 2, Phase 3
Sponsor	Shanghai Jiaolian Drug Research and Development Co., Ltd
Enrollment	216 participants

Key Eligibility Criteria

Inclusion (7)

- Subjects with primary membranous nephropathy pathologically confirmed by renal biopsy;
- Subjects with glomerular filtration rate eGFR e 45 mL/min/1.73 m2.
- If taking Angiotensin converting enzyme inhibitors/angiotensin II receptor antagonists/sodium-glucose cotransporter 2 inhibitors/endothelin inhibitors, a stable dose within 4 weeks before randomization;
- Subjects with 24-hour elevated urinary protein in accordance with the prescribed conditions;
- Subjects whose laboratory test results meet the prescribed standards during the screening period;

... and 2 more (see full listing online)

Exclusion (12)

- Subjects with secondary membranous nephropathy or primary membranous nephropathy whose pathological reports suggest concomitant crescent bodies;
- Subjects identified by the investigator as previously resistant to CD20 monoclonal antibody or cyclosporine;
- Subjects who have received medication prescribed for membranous nephropathy;
- Subjects with concomitant prescribed diseases;
- Subjects with a known history of severe allergic reactions to humanized monoclonal antibodies, or known allergies to any component of cyclosporine or B007;

... and 7 more (see full listing online)

Locations (21 total)

Beijing Tsinghua Changgung Hospital, Beijing, China
Peking university first hospital, Beijing, China
The Second Norman Bethune Hospital of Jilin University, Changchun, China
... and 18 more locations